CELZ — Stock Film
STOCK FILMSCENE 1/11CELZ · $1.28
Stock Expert AI presents
CELZ
Creative Medical Technology Holdings, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Creative Medical Technology Holdings, Inc. A quick introduction.

On the stock market since 2015, it operates in the world of health and science. It has 4 employees. Now — the numbers.

on the stock market since 2015
4 employees
$2.3M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1000.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 49% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$88K
2021
$89K
2022
$9K
2023
$11K
2024
$6K
2025
In the vault right now:
$0
DEBT: $14K
At this pace, that money lasts about 1.2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
7
very weak

Clearly below the class average.

FINANCIAL STRENGTH
41
weak

Clearly below the class average.

VALUATION
61
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
11
very weak

Clearly below the class average.

PRICE MOMENTUM
14
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 15 buys and 2 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $6.0M against $6K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, CELZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CELZ is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film